Phenomenex and USP Offer Workshop on Practical Application of Chapter <621>
News Feb 15, 2010
Phenomenex Inc., a global leader in the manufacture of separation science consumables, announces that it will be teaching a half-day course in conjunction with USP (U.S. Pharmacopeia) Professional Education on the practical application of Chapter <621> to improve HPLC method stability and speed. The course will be offered each day of Pittcon in Room SR-49 at the Orange County Convention Center in Orlando. The fee of $395 ($495 after February 19) includes conferee registration to Pittcon, course materials and refreshments. Course dates and times are:
Monday, March 1 1:00 – 5:00 p.m.
Tuesday, March 2 8:30 – 12:30 p.m.
Wednesday, March 3 1:00 – 5:00 p.m.
Thursday, March 4 8:30 – 12:30 p.m.
USP Chapter <621> defines the adjustments that labs may make to their LC methods without having to revalidate. The course, taught by top technical managers from Phenomenex and senior USP scientists, will use a combination of lecture and small group exercises to teach ways to adjust HPLC methods in various situations while adhering to the Chapter <621> guidelines. The course will be valuable for lab mangers, bench chemists and QA/AC analysts who work with USP monographs for pharmaceuticals and nutraceuticals. Participants may register online at http://www.usp.org/goto/usp621.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE